Dr. Riley Kirk (Canna Chem) on Cannabis Science, CHS, and Why Schedule 3 & Homegrow Matter

Send us Fan MailTom hosts a live cannabis legalization news show from a soon-to-open dispensary in Pekin, giving a brief tour of the sales floor, ID check area, vault, and planned community space, and noting the shop is expected to open in about three to four weeks after a three-year licensing process. The episode covers the FDA missing a cannabinoid-related deadline while acknowledging marijuana benefits but emphasizing concerns about children; a USDA Farm Bill draft that keeps the hemp definition and does not directly address hemp-derived intoxicating products; and backlash to a New York Times editorial calling for “guardrails” after previously backing legalization, with discussion about confusion between regulated cannabis and unregulated intoxicating hemp. They also mention Ohio Governor Mike DeWine urging people to stop complaining about new adult-use restrictions and a push to ban intoxicating hemp products, while citing developments in Chicago and Missouri and arguing hemp drinks and “marijuana labeled as hemp” will face increasing regulatory and banking pressure.Guest Dr. Riley Kirk (Canna Chem), PhD in pharmaceutical sciences and co-founder of a research/education nonprofit, discusses barriers to cannabis research under Schedule I and how Schedule III could expand research by enabling write-offs and reducing hurdles. She describes her group’s industry-funded work, including “Science of Smokeability,” focused on what makes smokable products high quality and safer. Kirk explains current theories around cannabinoid hyperemesis syndrome (CHS), including her survey-based study of 1,000+ people diagnosed or told they have CHS, common symptoms (notably early-morning nausea), and relief via hot showers linked to TRPV1 activation; she notes competing hypotheses such as high-potency frequent THC use, vaping, genetics, or mycotoxins.00:00 Live from the Dispensary: Show Kickoff & What’s Coming Up01:12 Behind the Scenes: Sales Floor Tour, Compliance Rules & Opening Timeline02:56 FDA Missed the Deadline: Cannabis Benefits, ‘Think of the Children’ & Admin Chaos05:23 Farm Bill Draft Breakdown: Hemp Definition, Total THC, and What’s (Not) Changing08:16 Hemp Drinks on Borrowed Time: Enforcement, Banking Risk & Political Reality Check15:54 Quick Dispensary Walkthrough: Vault Door, Restricted Areas & Build-Out Plans18:16 Meet Dr. Riley Kirk: Why Cannabis Research Is So Hard (and How It Gets Funded)22:52 Cannabinoid Hyperemesis Syndrome (CHS): Potency, Vapes, Genetics & Competing Theories29:08 Endocannabinoid Deficiency & Media Spin: Nuance vs Clickbait Cannabis Headlines32:46 “We Need More Studies” — ECS, Nervous System & What Science Is Missing34:15 Aging, Tolerance Shifts & the Entourage Effect Explained36:21 Homegrow, Trusting Inputs & Why ‘No Flower’ Medical Programs Fail39:18 Rescheduling to Schedule III: Validation, Pharma Capsules vs Flower44:39 What Research Is Next: Receptor-Level Effects & Better Strain Profiling46:47 Strain Spotlight: Gorilla Glue & Building a Flavor-Based ‘Menu’49:16 Beyond Terpenes: Flavor Chemistry, Ratio Strains & Fixing THC-Only Marketing50:59 CBD/CBG Demand, Hemp Market Changes & The Lab Testing Inflation Problem57:58 Consumer-Friendly Education: Activity-Based Recommendations & 1:1 Strains01:00:02 How CBD Works (and Why It Can Boost THC Experience) + Final Wrap & Where to Find Canna ChemSupport the showGet our newsletter: https://bit.ly/3VEn9vu